04 April 2013 | News | By BioSpectrum Bureau
Alchemia cancer drug gets patent protection
Singapore: Alchemia has been granted a further patent term adjustment for a key HyACT US patent, as well as an important additional patent further protecting its fondaparinux manufacturing platform in the US.
A review of a recently granted US HyACT patent, which is critical to Alchemia's platform oncology technology, has resulted in the patent term being adjusted by an additional 504 days. Patent 8,388,993, titled "Hyaluronan-Chemotherapeutic agent formulations for the treatment of colon cancer," provides US protection for the use of the company's proprietary drug HA-Irinotecan in the treatment of metastatic colorectal cancer. It also protects Alchemia's HyACT drug delivery platform as applied to a range of other anti-cancer drugs when used to treat drug resistant colorectal cancer.
Based on a Patent Term Adjustment (PTA) issued by the US Patent and Trade Mark Office (PTO), Alchemia previously reported the expiry date for this patent had been extended from July, 2021-to-November, 2023. However, the patent term has been further reassessed, and now extends out to March 24, 2025, subject to any terminal disclaimers or restrictions imposed by the US PTO.
In addition to the IP extension for HyACT, Alchemia has also been granted US patent 8,404,833, titled "Synthetic Heparin Disaccharides." This patent is part of a suite of patents securing the company's proprietary method of synthesis of intermediates for the manufacture of fondaparinux sodium, a generic anti-coagulant product already in market. The new patent has been granted through September, 2022. The parent patent (US 7,541,445) is entitled to a further 260 days of Patent Term Adjustment (PTA) beyond the September, 2022 term.
"We are pleased to see our IP protection significantly extended for our proprietary HyACT technology platform and to add another key patent to our fondaparinux suite," said Dr Mike West, VP, Intellectual Property, Alchemia. "With our IP stronger than ever, we look forward to the progression of both late stage HyACT technology and commercial stage fondaparinux toward enhanced patient outcomes in the US and beyond."